Fibrosis pathway modulation

"Fibrosis pathway modulation" is not a single molecule, receptor, or canonical drug target. Instead, it refers broadly to the therapeutic strategy of altering one or more molecular signaling pathways that drive the development and progression of fibrosis—a pathological process characterized by excessive deposition of extracellular matrix components leading to tissue scarring and organ dysfunction. Fibrosis can affect multiple organs including lung, liver, heart, kidney, and skin. Numerous molecular targets within these pathways have been identified as potential points for therapeutic intervention. Key examples include: - **Transforming growth factor-beta 1 (TGF‑β1) signaling**—a central driver in many forms of fibrosis; targeted by inhibitors such as Disitertide[2][9]. - **Lysophosphatidic acid receptor 1 (LPA1)**—implicated in idiopathic pulmonary fibrosis; antagonists like BMS‑986020 have shown clinical activity[3]. - **Peroxisome proliferator–activated receptors (PPARs)**—modulate macrophage activation states; agonists can reduce pro-fibrotic responses[6]. - **Tumor necrosis factor-alpha (TNF‑α) and interleukin signaling**—inflammatory cytokines involved in fibrogenesis; targeted by agents such as etanercept or infliximab[6][9]. Other notable modulated pathways include Notch signaling, hedgehog signaling, ferroptosis-related cell death mechanisms,[5] phosphodiesterase 4 inhibition,[3] necroptosis,[8] among others. Because "fibrosis pathway modulation" encompasses a wide array of molecules rather than a single defined entity—and because each component has its own set of aliases/abbreviations/drugs/biomarkers/safety concerns—it is not considered a canonical therapeutic target itself but rather an umbrella term describing an approach or field within drug discovery research. In summary: > "Fibrosis pathway modulation" is not a specific molecule or receptor but describes the broad strategy of therapeutically targeting key molecular drivers involved in fibrotic diseases. This includes numerous well-characterized proteins such as TGF‑β receptors, LPA receptors, PPARs, TNF family members, Notch/Hedgehog/Ferroptosis regulators among others. Each has distinct roles in signal transduction leading to fibroblast activation/proliferation/extracellular matrix production across various organs affected by fibrotic disorders.[1][2][3][5][6] For structured data extraction purposes on individual molecules/receptors/pathways implicated in fibrosis ("fibrogenesis"), refer instead to their specific names—for example "Transforming growth factor beta 1 receptor", "Lysophosphatidic acid receptor 1", etc.—rather than using this non-canonical umbrella term.